Hypoallergenic Safety Profile of a Novel Virus-like Particle Vaccine for the Treatment of Peanut Allergy supported by Skin Prick Testing
VLP Peanut is a novel subcutaneous VLP-based therapeutic vaccine being developed to treat peanut allergy. The first-in-human Phase I trial (PROTECT) is ongoing in the US, evaluating the safety and tolerability of VLP Peanut in healthy subjects and peanut allergic patients. The first part completed, evaluating skin reactivity to VLP Peanut using skin prick test (SPT) in peanut allergic patients. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Pieter-Jan de Kam, Roxanne Oriel, Thomas Casale, Kemi Oluwayi, Silvia Meneghesso, David Wilkie, Sema Eser, Marietta Krebs, Lena Oppenlaender, Eamonn McArdle, Matthias Kramer, Simon Hewings, Murray Skinner Source Type: research
MY006: allergen-targeted antibodies for the treatment of peanut allergy
Peanut allergy is one of the most common food allergies. There is a high unmet medical need, given the risk of sudden and severe allergic reactions due to accidental peanut exposure. Allergen-specific oral immunotherapy is currently the only treatment option. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Chiara Arena, Dimitri Bieli, Pascal Gasser, Sandra G ötschi, Rahel Scheibling, Tudor Ilca, Marta Paolucci, Valentine Homère, Delphine Bouis, Omayra Martin-Rodriguez, Pål Johansen, Kiave Ho Wang Yin, Barbara Ballmer-Weber, Alice Köhli, Tiziana Sonati, Source Type: research
Peanut oral immunotherapy plus omalizumab for 24 weeks safely induced tolerance at 48 weeks in allergic adults
Peanut oral immunotherapy (POIT) with or without omalizumab can improve tolerance in children. Data on adults are limited. We evaluated the safety and efficacy of POIT, combined with omalizumab, over 48 weeks in adults. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Jacqueline Loprete, Jonathan Montemayor, Robyn Richardson, Jamie Rogers, Winnie Tong, Andrew Carr Source Type: research
Skin and Airway Exposure to Allergens Promotes Development of Peanut allergy by Distinct Mechanisms in Mice.
The mechanisms of peanut allergy are not fully understood. T follicular helper (Tfh) cells that produce IL-13 (i.e., Tfh13 cells) are implicated in production of IgE antibody associated with anaphylaxis. The goal of this project was to elucidate the immunologic mechanisms involved in developing peanut allergy by using mouse models. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Mayumi Matsunaga, Jyoti Lama, Ryusuke Hayashi, Yuya Yoshida, Takao Kobayashi, Koji Iijima, Hirohito Kita Source Type: research
A diagnostic algorithm using peanut SPT and Ara h 2 sIgE reduces number of OFCs and cost of peanut allergy diagnosis in a clinical setting: a cost comparison analysis.
Two-step algorithms utilizing both SPT and ara h 2 sIgE demonstrate increased accuracy for diagnosing peanut allergy and fewer OFCs, in modelled studies. Since 2015, The Royal Children ’s Hospital, Australia (RCH) implemented a 2-step algorithm as a clinical guideline for peanut allergy diagnosis, recommending measurement of ara h 2 when SPT was 3-8mm (inclusive) when considering a peanut OFC. We determined whether uptake of this algorithm in a clinical setting reduced OFC need and whether there was a cost reduction compared to SPT alone. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Tim Brettig, Jennifer Koplin, Vicki McWilliam, Rachel Peters, Kirsten Perrett Source Type: research
Defining Cytokine Immune Profiles of Maternal Breast Milk Influencing Atopic Disease
The objective of this study is to define the immunological environment in human breast milk (BM) influencing the development of pediatric food allergy. We hypothesize that T-regulatory cytokines (IL-10 and TGF- β1) mediate the induction of milk, egg and peanut-specific tolerogenic antibodies and will be positively associated in BM. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Vibha Szafron, Brenda Bin Su, Warren Blackmon, Harold Ames, Christopher Holt, Daisy Tran, Danielle Guffey, Carla Davis Source Type: research
Epigenetic Predictors in Peanut Allergy: A Systematic Literature Review
Peanut allergies (PA) are potentially fatal, necessitating reliable exposure prophylaxis and improvements in our mechanistic understanding, including epigenetic modifications, heritable risk, and potential for epigenetic manipulation in immunotherapy. This review explores commonly identified epigenetic themes in PA. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Katarzyna Karpinska-Leydier, Arseni Khorochkov, Ambar Morales-Rodriguez, Gautam Maddineni, Laura Veras Mena Source Type: research
Sex Differences in Whole Blood Gene Expression in Infants at High Risk for Peanut Allergy
The study aimed to identify gene modules differentially expressed in male versus female infants at risk for peanut allergy. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Elizabeth Lippner, Rajesh Kumar, Abigail Lang, Sergejs Berdnikovs, Matthew Schipma, Samantha Gadd, Patrick McMullen, Hannah Aalemansour, Killian Buechler, John Kane, Hanli Fan, Demirkan Gursel Source Type: research
Treatment of Single and Multiple Food Allergies with ADP101: Results of the Harmony Phase 1/2 Trial
The phase 1/2 Harmony trial (NCT04856865) evaluated ADP101, a pharmaceutical-grade, investigational multifood oral immunotherapy (mOIT) for simultaneous treatment of allergy to 1-5 foods in ADP101 (almond, cashew, chicken ’s egg, codfish, cow’s milk, hazelnut, peanut, pecan, pistachio, salmon, sesame, shrimp, soy, walnut, wheat). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Daniel Petroni, Amy Archer, Mei-lun Wang, Lisa Tuomi, Shannon Bradley, Cheri Piscia-Nichols, Ashley Dombkowski, Dana McClintock Source Type: research
Long-Term Follow-up after IMPACT Peanut Oral Immunotherapy Clinical Trial
The IMPACT trial (NCT01867671) demonstrated strong desensitization and the potential for remission with peanut oral immunotherapy (OIT) in 1 –4-year-olds. Data on long-term outcomes of early intervention OIT are limited. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Jennifer Dantzer, Yamini Virkud, Amanda Cox, Stacie Jones, Sayantani Sindher, Kim Mudd, Nicholas Anania, Edwin Kim, Deanna Hamilton, Hugh Sampson, Jana Ayash, Keilaa-demi De La Cruz, Amy Scurlock, Safia Nawaz, Laurie Kost, R. Sharon Chinthrajah, Robert Wo Source Type: research
Evaluating Clinical Decision Support Tool for Early Peanut Introduction in a Pediatric Continuity Clinic
Early peanut introduction (PI) remains challenging in the primary care setting despite updated recommendations in the 2021 Consensus Approach to the Primary Prevention of Food Allergy Through Nutrition. We developed clinical decision support (CDS) tools for well child care (WCC) visits to aide providers in discussing PI. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Annabelle Rowland, Thinh Nguyen, Priscila Cunha, Swaminathan Kandaswamy, Tricia Lee Source Type: research
Comparison of safety and efficacy for peanut and tree nut oral immunotherapy (OIT) by age: infant OIT (iOIT) less then 12 months versus toddler OIT (tOIT) 1-4 years of age
Previous studies have shown an increased rate of desensitization and less adverse reactions to OIT in younger children less than 4 years compared to older children. There is limited data on OIT in ages less than 12 months. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Ahila Subramanian, Rachel Whitsel, Kara McNamara, Jaclyn Bjelac, Sandra Hong Source Type: research
Distinct metabolomic profiles are associated with changes over time and sustained unresponsiveness in children on peanut oral immunotherapy
Prior studies of food allergy have identified metabolomic pathways involved in immune function and allergy that are associated with having food allergies, but there is limited data around oral immunotherapy (OIT), desensitization, and immune tolerance. We aim to characterize metabolomic changes during desensitization through OIT. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Jennifer Styles, Sarita Patil, Bert Ruiter, Neal Smith, Clary Clish, Jessica Lasky-Su, Wayne Shreffler, Yamini Virkud Source Type: research
Joint transcriptomic and cytometric study of peanut allergic children reveals molecular and cellular cross-talk in reaction thresholds
Reaction thresholds in peanut allergy are highly variable. Elucidating causal relationships between molecular and cellular processes associated with variable thresholds could point to therapeutic pathways for raising thresholds. We thus characterized molecular and cellular systemic processes associated with reaction threshold in peanut allergy and causal relationships between them. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Lingdi Zhang, Yoojin Chun, Zoe Arditi, Galina Grishina, Tracy Lo, Kayla Wisotzkey, Charuta Agashe, Alexander Grishin, Julie Wang, Scott Sicherer, Cecilia Berin, Supinda Bunyavanich Source Type: research
IgE Binding and Cross-reactivity to Linear and Conformational Epitopes of Peanut and Walnut Vicilin-buried Peptides
Peanut-allergic individuals can exhibit clinically-relevant IgE cross-reactivity to various tree nuts, particularly walnut. Vicilin-buried peptides (VBPs) found in vicilin leader sequences (LS) are a new class of allergens in peanut and tree nuts that contribute to IgE cross-reactivity. The contribution of the linear and conformational epitopes to cross-reactivity of peanut and walnut VBPs is assessed here. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Lauren Swientoniewski, Ian Rambo, Jacqueline Nesbit, Hsiaopo Cheng, Stephen Gipson, Stacie Jones, Stephen Dreskin, Shahzad Mustafa, Scott Smith, Geoffrey Mueller, Soheila Maleki Source Type: research
